Leucine‐rich α‐2 glycoprotein is a predictive marker of therapeutic efficacy of the biologics in psoriatic arthritis
Guardado en:
Autores principales: | Yuka Shibata, Hideki Nakajima, Kimiko Nakajima, Satoshi Serada, Minoru Fujimoto, Tetsuji Naka, Shigetoshi Sano |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Wiley
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/c090de91f86641428a9bec3566a15ee0 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Anti‐MJ/NXP‐2 antibody‐positive adult‐onset dermatomyositis with lichen myxedematosus and endometrial carcinoma
por: Kimiko Nakajima, et al.
Publicado: (2021) -
Update on the treatment of psoriasis and psoriatic arthritis – role of apremilast
por: Forchhammer S, et al.
Publicado: (2015) -
Quality of life in patients with psoriatic arthritis
por: Kseniya Mikhailovna Koreshkova, et al.
Publicado: (2021) -
Assessing the effectiveness of synthetic and biologic disease-modifying antirheumatic drugs in psoriatic arthritis – a systematic review
por: Kingsley GH, et al.
Publicado: (2015) -
Blue nevus with a starburst pattern on dermoscopy
por: Takeo Shiga, et al.
Publicado: (2012)